MedTrace Logo

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

NCT04890509 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2024-10-16

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19).

Conditions

Interventions

DRUG

Bemcentinib

Bemcentinib capsules will be administered orally.

OTHER

SoC

The SoC will be administered based on local guidelines.

Sponsors & Collaborators

  • BerGenBio ASA

    lead INDUSTRY

Principal Investigators

  • Hani Gabra · BerGenBio ASA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2021-05-25
Completion
2021-05-25

Countries

  • India
  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04890509 on ClinicalTrials.gov